From Wikipedia, the free encyclopedia
|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||236.231 g·mol−1|
|3D model (JSmol)|
Carbazochrome is an antihemorrhagic, or hemostatic, agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound. It is hoped that this drug can be used in the future for preventing excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on its effectiveness and the severity of possible side effects remains to be fairly inconclusive.
Carbazochrome, the semicarbazone of adrenochrome, that interacts with α-adrenoreceptors on surface of platelets, which are coupled to Gq protein and initiate PLC IP3/DAG pathway to increase intracellular free calcium concentration with these subsequent actions:
- Activates PLA2 and induce arachidonic acid pathway to synthesize endoperoxides (TxA2, thromboxane A2)
- Calcium binds to calmodulin which then binds and activates myosin light-chain kinase, that will enable the myosin crossbridge to bind to the actin filament and allow contraction to begin. This will change platelet's shape and induce release of serotonin, ADP, vWF (Von Willebrand factor), PAF (Platelet-activating factor) to promote further aggregation and adhesion.
- Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro GS (2001). "Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study". Curr Med Res Opin. 17 (4): 256–61. doi:10.1185/030079901753403144. PMID 11922398.
- Squadrito F, Altavilla D, Oliaro Bosso S (2000). "Double-blind, randomized clinical trial of troxerutin-carbazochrome in patients with hemorrhoids". Eur Rev Med Pharmacol Sci. 4 (1–2): 21–4. PMID 11409185.
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.